In the clinical trial of the new drug division of HongRi pharmaceutical sepsis 1.1

HongRi Pharmaceutical (300026) said Friday (September 18) that the company's new sepsis class 1.1 drug is currently in clinical trials The main business of HongRi pharmaceutical is the R & D, production and sales of Chinese patent medicine and Western medicine The eighth meeting of the Fourth Board of directors of HongRi Pharmaceutical Co., Ltd was held on November 19, 2010, and the proposal on the cooperation between the use of over raised funds and the First Affiliated Hospital of the Third Military Medical University of the people's Liberation Army in the development and treatment of class I new drugs for sepsis was reviewed and passed (the hospital is hereinafter referred to as Southwest Hospital) the company plans to use the over raised funds for the project, and pay them by stages according to the R & D progress The total investment of the project is expected to be 42.85 million yuan The company and Southwest Hospital jointly carry out the entrusted research and joint development, including 5 million yuan of transfer fee in the early stage, 9.85 million yuan of pre clinical research fund and 2 yuan of clinical trial fund, 3 million yuan, 5 million yuan for the pilot test of APIs and preparations, etc if the over raised funds are insufficient, the self owned funds will be used By consensus, the results of the project belong to the following ways: both the company and southwest hospital are patent inventors, the name of both parties signing the new drug certificate, and the production approval will be owned exclusively by the company Estimated work progress: (1) apply for clinical trials before May 31, 2012; (2) apply for new drug certificate and production approval before December 31, 2017; (3) organize production before May 2019 It is estimated that the new drug will be launched in 2019 Comments: this project is in line with the company's long-term development plan After successful implementation, it will produce the first class I new drug for sepsis treatment in China, which can effectively support the company to achieve the goal of occupying the domestic sepsis drug market and is expected to enter the international market At the same time, the use of over raised funds and the cooperation of Southwest Hospital in the development and treatment of sepsis class I new drugs does not conflict with the implementation of the company's fund-raising investment project, and does not affect the normal progress of the company's fund-raising investment project Xuebijing injection is the only national class II new drug approved by SFDA for the treatment of sepsis and multiple organ dysfunction syndrome in China It is the exclusive compound injection of traditional Chinese medicine produced by the company At present, there is a lack of class I innovative drugs for the treatment of sepsis in China, so if the project can be successfully implemented, its market prospects are good At present, based on the R & D speed of the company's project products, it is expected that the risk of similar products participating in the competition is relatively small Once the product is successfully developed and successfully launched in 2019, it will not only break the current situation of lack of supply of class I new drugs for sepsis treatment in the market, but also take this product as an opportunity to monopolize the market share of this part, forming the company's core competitiveness and exclusive discourse in this field Right; but from the perspective of double-edged sword analysis, when we see that this project may create benefits and markets for the company, we also need to make clear the risks that may be expected to be borne by the implementation of this project, mainly including the risk of project research failure, technical risk, intellectual property risk and other new drug progress for the treatment of sepsis due to the general uncertainty in the research and development of class I new drugs Market risks caused by entering the domestic market To sum up, the company has both advantages and risks in this project However, in view of the current international and domestic market situation of sepsis drugs, the research and development strength of Southwest Hospital as the only long-term and systematic research and development institution engaged in anti sepsis new drugs research in this field and the analysis of the policy spirit of the state to encourage the development of major innovative drugs, we are optimistic about the future development of the company At the same time, investors are advised to pay attention.